Konjungtivitis Trakoma

01Pathophysiology

Trachoma is caused by repeated conjunctival infection with Chlamydia trachomatis serotypes A, B, Ba, and C. These serotypes are distinct from those causing urogenital chlamydial disease (D-K) and lymphogranuloma venereum (L1-L3). The organism is an obligate intracellular bacterium that targets conjunctival epithelial cells, where it undergoes its characteristic biphasic life cycle: the elementary body (infectious, extracellular form) attaches to and enters the cell, then converts into a reticulate body (metabolically active, replicating form) within a membrane-bound inclusion. After replication, reticulate bodies condense back into elementary bodies and are released upon cell lysis, perpetuating the cycle.

The disease does not cause blindness through a single infection. Rather, it is the result of repeated reinfections over years, typically beginning in early childhood. Each episode of active infection triggers a type IV hypersensitivity response (cell-mediated immunity) in the conjunctiva, predominantly involving CD4+ T cells and macrophages. This chronic inflammatory infiltrate is what produces the characteristic lymphoid follicles visible on the upper tarsal conjunctiva. The follicles represent organized collections of lymphocytes and are the hallmark of active trachoma.

Over time, the repeated cycles of infection and immune-mediated inflammation lead to progressive subepithelial fibrosis of the tarsal conjunctiva. This scarring contracts the tarsal plate, causing the eyelid margin to rotate inward, a condition known as entropion. Once entropion develops, the eyelashes are directed against the corneal surface, a finding called trichiasis. The constant mechanical abrasion of lashes on the cornea results in corneal epithelial damage, secondary bacterial infection, corneal pannus (fibrovascular ingrowth), and ultimately corneal opacification, which is the direct cause of irreversible blindness.

This progression from active infection to blindness typically spans decades, which is why active disease peaks in children (ages 1-5) but blindness predominantly affects adults (over age 40), particularly women, who have higher rates of exposure through close contact with infected children.

02Classification and Clinical Manifestation

The WHO simplified trachoma grading system is the standard classification used in clinical practice and is highly testable:

The key clinical concept is that TF and TI represent active, infectious disease (targeted by antibiotics and hygiene measures), while TS, TT, and CO represent the cicatricial sequelae (requiring surgical intervention for TT). A patient can have both active inflammation and scarring simultaneously.

Herbert pits are another classic finding worth highlighting. These are small depressions or pits at the superior limbus (the junction of cornea and sclera) that represent resolved limbal follicles. They are considered pathognomonic for prior trachoma and are frequently described in vignettes as a clue to the diagnosis.

03Diagnostic Workup

Trachoma is primarily a clinical diagnosis, especially in endemic settings where laboratory resources are limited. The WHO simplified grading system was designed precisely for this purpose: a trained health worker everts the upper eyelid and examines the tarsal conjunctiva for follicles, inflammation, and scarring. No special equipment beyond a magnifying loupe and adequate light is required. In an exam vignette, the description of follicles on the everted upper tarsal plate in a child from an endemic region is sufficient to establish the diagnosis.

When laboratory confirmation is needed, Giemsa staining of conjunctival epithelial scrapings can reveal the characteristic basophilic intracytoplasmic inclusion bodies, which represent the chlamydial inclusions within host cells. However, sensitivity is limited, particularly in chronic or low-grade infections.

NAAT (PCR) is the most accurate test available, offering the highest sensitivity and specificity for detecting C. trachomatis in conjunctival swabs. It is used primarily in research, epidemiologic surveys, and when clinical diagnosis is uncertain. If a question asks for the "most accurate" or "confirmatory" test, NAAT is the answer.

An important distinction to remember: serology is not useful for diagnosing active trachoma. Because C. trachomatis infections are so common (including urogenital serotypes), serum antibodies are not specific enough to confirm ocular disease with trachoma-associated serotypes.

04Management and Treatment

The cornerstone of trachoma control is the SAFE strategy, endorsed by the WHO as an integrated public health approach. Each letter represents one pillar, and all four must be implemented together for elimination to succeed.

Surgery is indicated for patients with trachomatous trichiasis (stage TT). The procedure of choice is the bilamellar tarsal rotation, in which a full-thickness incision is made through the scarred tarsal plate and the distal segment is rotated outward to redirect the lashes away from the cornea. This is a relatively simple procedure that can be performed by trained non-physician health workers in the field. Without surgery, trichiasis leads to progressive corneal abrasion, ulceration, and blindness. Epilation (manual removal of offending lashes) is a temporizing measure but not definitive, as lashes regrow.

Antibiotics target active infection (stages TF and TI). Oral azithromycin is preferred because it is given as a single dose (20 mg/kg in children, 1 g in adults), making it ideal for mass drug administration campaigns. In endemic communities, the entire population may be treated annually for 3-5 years to reduce the reservoir of infection. The alternative is topical tetracycline 1% ointment applied twice daily for 6 weeks, but adherence is far lower.

Facial cleanliness and environmental improvement are the prevention components. Transmission occurs through direct contact with ocular or nasal secretions, fomites (shared towels, bedding), and mechanical vector transfer by flies that breed in human feces and are attracted to facial discharge. Improving water access for face-washing, constructing latrines to reduce fly breeding sites, and reducing household overcrowding are all essential.

Regarding contraindications: azithromycin should be used cautiously in patients with hepatic impairment. In children under 6 months of age, topical tetracycline is preferred over systemic azithromycin.

05Differential Diagnosis and Distractors

The single most important discriminator in a vignette is the location of follicles. Trachoma characteristically produces follicles on the upper tarsal conjunctiva, whereas adult inclusion conjunctivitis predominantly involves the lower fornix and lower tarsal conjunctiva. This anatomic distinction is a reliable way to differentiate the two chlamydial eye diseases.

06Traps and High-Yield Pearls

The most common trap with trachoma questions is confusing the serotypes. Students frequently mix up the chlamydial serotypes: A-C cause trachoma (ocular), D-K cause urogenital disease and inclusion conjunctivitis, and L1-L3 cause lymphogranuloma venereum. A vignette describing follicular conjunctivitis in a sexually active adult with concurrent urethritis is inclusion conjunctivitis (D-K), not trachoma, even though both are caused by the same organism.

Another frequent mistake is thinking that a single episode of chlamydial conjunctivitis causes blindness. Trachoma-related blindness requires years of repeated reinfection and is a disease of cumulative scarring. If a vignette presents a child with a single episode of follicular conjunctivitis, the concern is treatment and prevention of reinfection, not imminent visual loss.

Students also commonly forget that trachoma is the leading infectious cause of preventable blindness worldwide. This phrase appears frequently in question stems and should immediately trigger recognition.

When a question asks about treatment, the expected answer is almost always oral azithromycin (single dose) rather than topical therapy, because single-dose treatment is the pillar of mass drug administration programs. However, if the question stem mentions trichiasis or eyelash-cornea contact, the answer shifts to surgical correction (bilamellar tarsal rotation) as the next best step, because antibiotics alone will not reverse structural scarring.

Finally, remember the mnemonic embedded in the SAFE strategy itself: the components are tested in order of clinical urgency. Surgery addresses the immediate threat to vision (trichiasis), antibiotics treat the active infection, and facial cleanliness plus environmental improvement prevent future transmission. The core competency being tested is the ability to match the correct intervention to the correct stage of disease.